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Objective: To examine the relationship between pa-
tient-rated physician empathy and outcome of bo-
tulinum toxin treatment for post-stroke upper limb 
spasticity.
Design: Cohort study.
Subjects: Twenty chronic stroke patients with upper 
limb spasticity.
Methods: All patients received incobotulinumtoxinA 
injection in at least one muscle for each of the fol-
lowing patterns: flexed elbow, flexed wrist and clen-
ched fist. Each treatment was performed by 1 of 5 
physiatrists with equivalent clinical experience. Pa-
tient-rated physician empathy was quantified with 
the Consultation and Relational Empathy Measure 
immediately after botulinum toxin treatment. Pa-
tients were evaluated before and at 4 weeks after 
botulinum toxin treatment by means of the following 
outcome measures: Modified Ashworth Scale; Wolf 
Motor Function Test; Disability Assessment Scale; 
Goal Attainment Scaling.
Results: Ordinal regression analysis showed a signi-
ficant influence of patient-rated physician empathy 
(independent variable) on the outcome (dependent 
variables) of botulinum toxin treatment at 4 weeks 
after injection, as measured by Goal Attainment Sca-
ling (p < 0.001).
Conclusion: These findings support the hypothesis 
that patient-rated physician empathy may influence 
the outcome of botulinum toxin treatment in chronic 
stroke patients with upper limb spasticity as measu-
red by Goal Attainment Scaling. 
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Stroke is a leading cause of adult disability (1, 2). Damage to the descending tracts and sensory-
motor networks results in the positive and negative 
signs of the upper motor neurone syndrome (UMNS) 
(1–3). The upper limb is commonly involved after 
stroke, with up to 69% of patients having arm weakness 
on admission to hospital (4). Recovery of upper limb 
function has been found to correlate with the degree 
of initial paresis and its topical distribution according 
to the cortico-motoneuronal representation of arm 
movements (5–9). 
Spasticity is a main feature of UMNS. It is defined 
as a state of increased muscle tone with exaggerated 
reflexes characterized by a velocity-dependent increase 
in resistance to passive movement (10). Upper limb 
spasticity has been found to be associated with reduced 
arm function, low levels of independence and high 
burden of direct care costs during the first year post-
stroke (11). It affects nearly half of patients with initial 
impaired arm function, with a prevalence varying from 
17% to 38% of all patients at one year post-stroke (11). 
Up to 13% of patients with stroke need some form of 
spasticity treatment (drug therapy, physical therapy or 
other rehabilitation approaches) within 6–12 months 
post-onset (11, 12). Botulinum toxin type A (BoNT-A) 
has been proven safe and effective for reducing upper 
limb spasticity and improving arm passive function in 
adult patients (13, 14). While current literature reports 
highly patient-specific potential gains in function after 
BoNT-A treatment, there is inadequate evidence to 
determine the efficacy of BoNT-A in improving active 
function associated with adult upper limb spasticity 
(13).
Empathy refers to the ability to understand and share 
the feelings, thoughts or attitudes of another person 
(15). It is an essential component of the physician-
patient relationship and a key dimension of patient-
centred care (15, 16). This is even more important in 
rehabilitation medicine, where persons with disabilities 
often report encountering attitudinal and environmental 
barriers when trying to obtain rehabilitative care and 
express the need for better communication with their 
healthcare providers (17).
To the best of our knowledge, no previous research 
has investigated the influence of physician empathy 
on patient outcome after spasticity treatment. The aim 









































411Physician empathy and outcome of botulinum toxin
patient-rated physician empathy and clinical outcome 
of BoNT-A treatment for upper limb spasticity due to 
chronic stroke.
METHODS
This was a single-centre cohort study. Inclusion criteria were 
as follows: age greater than 18 years; upper limb spasticity 
resulting from ischaemic or haemorrhagic stroke (documented 
by a computerized tomography or magnetic resonance imaging 
scan; subarachnoid haemorrhage and transient ischaemic at-
tack excluded); elbow, wrist and finger flexors tone grade of 
at least 1+ on the Modified Ashworth Scale (MAS) (18); time 
since stroke onset at least 6 months and time since last BoNT-A 
treatment at least 5 months. Exclusion criteria were as follows: 
participation in other clinical trials; depression (Beck Depres-
sion Inventory II score > 13) (19); fixed contractures (tone grade 
of 4 on the MAS) or bony deformities in the affected upper 
limb; previous treatment of the affected upper limb spasticity 
with neurolytic or surgical procedures; other neurological or 
orthopaedic conditions involving the upper limbs. Participants 
were recruited from among the outpatients consecutively admit-
ted to the spasticity service our clinical unit during the period 
from October 2015 to June 2016.
Written informed consent for participation in the study was 
obtained from all participants. The study was carried out accor-
ding to the tenets of the Declaration of Helsinki and approved by 
the local ethics committee. Participants were not allowed to take 
part in any type of physical rehabilitation during the 3 months 
before entering the study (as certified by the participant’s general 
practitioner) or home exercise programme for the duration of 
the study. Moreover, to minimize potential confounding factors, 
participants were requested to avoid stretching for the duration 
of the study. When appropriate, participants were referred to an 
intensive rehabilitation programme on completion of the study 
according to the recommendations of the local ethics committee.
IncobotulinumtoxinA (Merz Pharma GmbH, Frankfurt, 
Germany) was injected into at least one muscle for each of the 
following upper limb spasticity patterns: flexed elbow (biceps 
brachii; brachialis; brachioradialis), flexed wrist (flexor carpi 
radialis; flexor carpi ulnaris), and clenched fist (flexor digitorum 
superficialis; flexor digitorum profundus). The incobotulinumt-
oxinA dose (dilution 100 U/2 ml in saline 0.9%) was 100 U for 
the biceps brachii, 75 U for the brachialis, 50 U for the brachio-
radialis, 50 U for the flexor carpi radialis, 50 U for the flexor 
carpi ulnaris, 75 U for the flexor digitorum superficialis and 75 
U for the flexor digitorum profundus. B-mode real-time ultra-
sonography was performed using a MyLab 70 XVision system 
(Esaote SpA, Genoa, Italy) interfaced with a linear transducer 
(scanning frequency 13 MHz) to guide needle positioning into 
the targeted muscle at each injection site. The transducer was 
positioned in the transverse view, perpendicular to the affected 
upper limb surface and the needle was inserted into the targeted 
muscle at a 30° angle to the transducer (20, 21). Immediately 
after BoNT-A administration, all patients received a 60-min ses-
sion of electrical stimulation of the injected muscles (rectangular 
current pulses, 4 Hz, 0.2 ms, intensity adjusted to elicit visible 
muscle contraction) (22). No other physical therapy, casting, ta-
ping or stretching procedures were done during the study period. 
Each treatment was performed by 1 of 5 physiatrists (who 
were unaware of the study aims and protocol) with equivalent 
experience (more than 3 years) in spasticity management with 
BoNT-A. According to their routine clinical practice, they eva-
luated the outcome of BoNT-A treatment immediately before 
and at 4 weeks after injection. Outcome measures were: the 
MAS (18), the Wolf Motor Function Test – Functional Ability 
Scale (WMFT-FAS) (23), the Disability Assessment Scale 
(DAS) (24) and the Goal Attainment Scaling (GAS) (25). The 
MAS is a 6-point scale that grades the resistance of a relaxed 
limb to rapid passive stretch (0: no increase in muscle tone; 1: 
slight increase in muscle tone at the end of the range of mo-
tion; 1+: slight increase in muscle tone through less than half 
of the range of motion; 2: more marked increase in muscle tone 
through most of the range of motion; 3: considerable increase 
in muscle tone; 4: joint is rigid) (18). For statistical purposes, 
a score of 1 was considered as 1, a score of 1+ as 2 and so on 
up to a score of 4, which was considered as 5 (26). Fifteen 
function-based tasks on the WMFT-FAS were used to assess 
the functional ability of the affected arm as follows: forearm to 
table (side); forearm to box (side); extend elbow (side); extend 
elbow (weight); hand to table (front); hand to box (front); reach 
and retrieve; lift can; lift pencil; lift paper clip; stack checkers; 
flip cards; turn key in lock; fold towel; lift basket. The quality 
of movement for each task was rated on a 6-point scale from 
0 (does not attempt) to 5 (movement appears to be normal). 
Scores range from 0 to 85 (23). The DAS evaluates the extent of 
functional impairment in the areas of patient hygiene, dressing, 
limb position, and pain according to the following scale: 0 = no 
disability; 1 = mild disability; 2 = moderate disability; 3 = severe 
disability (24). The GAS is a method for scoring the extent to 
which a patient’s individual goals are achieved during the course 
of an intervention (25). For the purposes of this study, the main 
problem areas before BoNT-A treatment were identified, then 
the patient weighted 2 goals on a 4-point scale, where 0 = not at 
all important; 1 = slightly important; 2 = moderately important; 
3 = very important. Similarly, the physician weighted the goals 
in terms of the anticipated difficulty to achieve them on the same 
4-point scale. The goal weight was importance × difficulty. At 
4 weeks after treatment, each goal was rated on a 5-point scale 
according to the degree to which it was attained: –2 = much less 
than the expected outcome; –1 = somewhat less than the expec-
ted outcome; 0 = expected level of outcome; 1 = somewhat more 
than the expected outcome; 2 = much more than the expected 
outcome. The goal attainment “T-score” was calculated using 
a spreadsheet calculator (25). 
Immediately after BoNT-A treatment, another examiner, 
who was not involved in the treatment, evaluated all patients, 
recording the office waiting time to see the physician (time 
elapsed from front office registration until the attending 
physician entered the room), the duration of the visit, and the 
time from submitting a consultation request to receiving an 
appointment. In addition, the examiner measured patient-rated 
physician empathy by means of the Consultation and Relatio-
nal Empathy Measure (CARE), which is a validated 10-item 
questionnaire that investigates the patient’s perception of the 
physician’s empathic understanding and behaviour during the 
visit (Appendix I). Each response is marked on a 5-point scale, 
where responses range from 1 (poor) to 5 (excellent). The score 
was obtained from the sum of all items (maximum score 50; 
minimum score 10) (27).
Statistical analysis was carried out using the Statistical 
Package for Social Science for Macintosh, version 20.0 (IBM 
Corp., Armonk, NY, USA). Pre-study power calculation esti-
mated that a total of 13 patients would provide 95% power to 
detect a difference of one point on the MAS (SD = 0.9) after 
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treatment (28). Ordinal regression analysis was performed to 
evaluate the influence of patient-rated physician empathy (inde-
pendent variable) on the improvements found at 4 weeks after 
BoNT-A treatment, as measured on the MAS, the WMFT-FAS, 
the DAS and the GAS (dependent variables). The Spearman 
rank correlation test was performed to assess the association 
between patient-rated physician empathy and demographic/
organizational characteristics (age of patients and physicians, 
physicians’ years of practice, time since stroke onset, office wai-
ting time to see the physician, duration of consultation and time 
from consultation request to actual appointment). Within-group 
comparisons were performed with the Wilcoxon signed-rank 
test. The alpha level for significance was set at p < 0.05 with no 
correction for multiple comparisons.
RESULTS
Seventy-five potentially eligible, consecutive out-
patients were examined. Fifty-five patients met the 
exclusion criteria and were not included in the study. 
Twenty chronic stroke patients (16 men and 4 women; 
mean age 64.8 years) with upper limb spasticity (mean 
time since stroke onset 6.1 years) were confirmed 
eligible and included in the study. No adverse events 
occurred during the study. All patients included in the 
study completed all evaluations and were analysed. 
Tables I and II present the patients’ demographic and 
clinical features.
The ordinal regression analysis showed a significant 
influence of patient-rated physician empathy, as mea-
sured by the CARE (independent variable) on the GAS 
(p < 0.001) but not on the MAS (elbow: p = 0.324; wrist: 
p = 0.506; fist: p = 0.720), the WMFT-FAS (p = 0.476) 
and the DAS (hygiene: p = 0.453; dressing: p = 0.453; 
limb position: p = 0.233; pain: p = 0.935). As reported 
in Table III, the Spearman correlation showed a signi-
ficant direct association between the CARE score and 
patients’ age (p = 0.016; ρ = 0.532).
Within-group comparisons showed significant im-
provements on the MAS after BoNT-A treatment at the 
affected elbow (p = 0.003; Z = –3.002), wrist (p = 0.007; 
Z = –2.714) and fist (p = 0.001; Z = –3.250). Within-
group comparisons showed significant improvements 
in the WMFT-FAS scores after BoNT-A treatment at 
the affected upper limb (p = 0.003; Z = –2.937). Within-
group comparisons showed significant improvements 
in the DAS scores after BoNT-A treatment at the af-
fected upper limb in the areas of hygiene (p = 0.046; 
Z = –2.000), dressing (p = 0.046; Z = –2.000) and limb 
position (p = 0.011; Z = –2.530). Table IV presents 
the data on patient performance at pre-treatment and 
post-treatment evaluations and the results of the within-
group comparisons.
Table I. Demographic and clinical features of patients
Variables
Age of patients, years, mean (SD) 64.8 (11.8)
Sex of patients, male/female, n 16/4
Time from stroke, years, mean (SD) 6.1 (3.6)
Age of physicians, years, mean (SD) 41.1 (7.9)
Physicians’ years of practice, years, mean (SD) 14.1 (7.8)
Time from request, days, mean (SD) 36.5 (13.1)
Waiting time, min, mean (SD) 9.8 (3.8)
Duration of consultation, min, mean (SD) 42.3 (14.9)
SD: standard deviation. 
Table II. Goal Attainment Scaling choose according to the 
World Health Organization (WHO) International Classification of 
Functioning, Disability and Health (ICF) classification
WHO ICF classification
Total goals set (n)
Domain and goal area Primary code
Body Functions
Pain b280 1
Passive movement/range b735/b710 8
Reducing associated reactions b755 2
Simple hand/arm movements b760 5
Activities and Participation
Upper limb activities
Lifting and carrying objects d430 2
Fine finger use/dexterity d440 4
Holding, grasping objects d445 2
Self care
General independence d500 2




Meal preparation/cooking d630 2
Household tasks d640 2
Community
Recreation/leisure/hobbies d920 2














Age of patients 1.000
Time from stroke onset 0.074 1.000
Age of physicians 0.106 0.178 1.000
Physicians’ years of practice 0.106 0.178 1.000* 1.000
Time from request –0.278 0.166 0.189 0.189 1.000
Waiting time 0.271 –0.081 0.063 0.063 0.301 1.000
Duration of consultation 0.057 0.182 –0.317 –0.317 –0.137 –0.198 1.000
CARE 0.532* –0.239 –0.017 –0.017 –0.216 0.079 –0.101 1.000
*p < 0.05. 
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DISCUSSION
Consistent with the aim of this single-centre cohort 
study, our findings support the hypothesis that patient-
rated physician empathy (as measured on the CARE) 
may influence the outcome of BoNT-A treatment for 
upper limb spasticity in chronic stroke patients, as 
measured on the GAS. Measurement of spasticity is 
an important part of stroke patient care (29). Guideli-
nes for the management of upper limb spasticity have 
highlighted the importance of measuring the impact of 
interventions at the level of improved function and care 
needs (30). Unfortunately, obtaining accurate measu-
rements of spasticity is challenging because the nature 
of spasticity may be quite elusive and assessment is 
frequently subjective, including evaluation of passive 
and active function and self-efficacy measures (13, 24, 
25, 29, 31). In clinical practice as in scientific research, 
the MAS (or its original version) is the most commonly 
used method for measuring spasticity (32, 33). Howe-
ver, because of its methodological limitations, it has 
been suggested that the MAS should not be applied 
as a single outcome measure. Instead, newer methods 
that take into account the needs of patients with upper 
limb spasticity should be used in the evaluation of limb 
function, not only during clinic attendance, but also 
within the context of everyday real-life activities (30, 
32, 34). On this basis, we employed 3 main categories 
of methods to evaluate (active or passive) function as 
follows: the patient report on some upper-limb items 
(including the DAS), the composite measure of fun-
ction (incorporating patient-reported items) and the 
GAS that sets goals for intervention involving patients, 
carers and clinicians (30).
Botulinum toxin demonstrated a clinically signi-
ficant effect on goal attainment for the real-life ma-
nagement of upper limb spasticity following stroke 
(33). When interpreting this observation, however, we 
should remember that goal attainment depends not only 
on the patient’s ability to meet the goal, but 
also on the accuracy of expected outcomes 
prediction and the ability to negotiate treat-
ment objectives, which, in turn, relies upon 
high-level negotiating skills to establish 
realistic expectations and set (challenging 
but) achievable goals (35). Good interper-
sonal communication skills are critical for 
negotiating and agreeing on realistic treat-
ment goals with the patient. In this context, 
physician empathy may be considered a 
key determinant of goal attainment after 
BoNT-A treatment in adults with upper limb 
spasticity due to stroke. Our findings are in 
keeping with these concepts. Indeed, we 
observed a significant relationship between 
patient-rated physician empathy (CARE) 
and the GAS score. From this perspective, in order 
to critically discuss our results, we have to consider 
that one of the main limitations of the GAS is that 
pessimistic goals might be more susceptible to obtain 
higher gains than optimistic ones. Furthermore, some 
patients may often be unable to recognize and rate their 
pre-defined goal achievements, providing “desirable” 
answers rather than those that reflect their actual level 
of goal attainment (36). In addition, we have to take 
into account that each goal defined by the GAS should 
be of interest and relevant to the patient reflecting his/
her reflect expectations, wishes and priorities, as well 
as those of carers and family members (36, 37). Thus, 
it is likely that some goals defined by the patients 
involved in this study would not be SMART ones 
(specific, measurable, achieveable, realistic/relevant 
and timed) and, consequently, their attainment was 
evaluated by means of subjective opinion (37). In our 
view, considering the great empathic load required, 
not only by the clinical management of chronic stroke 
patients with upper limb disability, but also in order 
to obtain the effective collaborative involvement of 
both the patients and carers during the goal-setting 
and follow-up processes, it is highly plausible that 
the positive relationship with the physician would 
have influenced the BoNT-A treatment outcome as 
measured by the GAS. On this basis, the GAS should 
not be considered as a clinical measure focused on 
spasticity assessment, but instead as a gauge of those 
symptoms, behaviours, feelings, skills or achievements 
that a specific therapeutic intervention is designed to 
change in order to organize, focus and clarify the aims 
of treatment (38).
As to the other outcomes evaluated in the current 
study, we failed to find significant relationships with 
the CARE. This was probably because passive soft-
tissue stretching, functional ability and functional 








After treatment vs 
before treatment
p-value (z)
MAS elbow (0–5) 2.00 (1.25; 3.00) 1.00 (1.00; 2.00) 0.003 (–3.002)*
MAS wrist (0–5) 2.00 (1.00; 3.00) 1.00 (1.00; 2.00) 0.007 (–2.714)*
MAS fist (0–5) 3.00 (2.25; 3.75) 2.00 (1.00; 2.75) 0.001 (–3.250)*
WMFT – FAS (0–85) 16.50 (1.25; 28.28) 22.50 (1.25; 35.75) 0.003 (–2.937)*
DAS hygiene (0–3) 1.00 (0.00; 2.00) 1.00 (0.00; 2.00) 0.046 (–2.000)*
DAS dressing (0–3) 1.50 (0.25; 2.00) 1.00 (0.00; 2.00) 0.046 (–2.000)*
DAS limb position (0–3) 1.00 (0.00; 2.00) 0.50 (0.00; 1.75) 0.011 (–2.530)*
DAS pain (0–3) 0.00 (0.00; 0.00) 0.00 (0.00; 0.00) 0.180 (–1.342)
CARE (10–50) 49.50 (40.00; 50.00)
GAS (T-score), mean (SD) 52.55 (9.38)
*p < 0.05. MAS: Modified Ashworth Scale; IQR: interquartile range; WMFT-FAS: Wolf Motor 
Function Test – Functional Ability Scale; DAS: Disability Assessment Scale; CARE: Consultation 
and Relational Empathy Measure; GAS: Goal Attainment Scaling; SD: standard deviation. 
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impairment are less influenced by physician empathy 
because of their focal evaluation (see the MAS and 
the WMFT-FAS) as well as the definition of SMART 
evaluation criteria (see the MAS, the WMFT-FAS and 
the DAS). Interestingly, we also observed a significant 
direct association between patient-rated physician 
empathy and patient age. This observation is shared 
by findings in the general emotion literature, which 
showed that older adults have better emotion regula-
tion abilities than young adults according to self-report 
data, which suggests that older adults may have better 
empathic understanding than young people (39).
The current study has several limitations. First, this 
was a single-centre study. This may have reduced the 
impact of some organizational aspects (such as office 
waiting time, visit duration, and the time from consul-
tation request to actual appointment), as well as may 
relate to the high CARE score obtained, given that the 
5 physicians involved in this study work in the same 
clinical service and might have similar attitudes. In 
this respect, we also exclude the risk that the targeted 
muscles were not chosen in relation with the GAS 
because, according to their clinical service routine, 
the GAS is taken into account to choose the target 
muscles of BoNT-A treatment. Secondly, no long-term 
(more than 1 month) follow-up was planned. Thirdly, 
lower limb spasticity was not evaluated. Fourthly, we 
did not include paediatric patients and so we cannot 
draw conclusions about the influence of patient-rated 
physician empathy on the outcome of BoNT-A treat-
ment in children. 
In conclusion, the findings of this study support the 
hypothesis that patient-rated physician empathy may 
influence the outcome of BoNT-A treatment in chronic 
stroke patients with upper limb spasticity. In order 
to further validate our findings, future larger studies 
should address these issues and the role of empathy 
during post-injection rehabilitation treatment (40).
The authors declare no conflicts of interest.
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Appendix I. The Consultation and Relational Empathy Measure
How the doctor was… Poor Fair Good Very good Excellent
1) Making you feel at ease… 
    (being friendly and warm towards you, treating you with respect; not cold or abrupt)
1 2 3 4 5
2) Letting you tell your ”story”…
    (giving you time to fully describe your illness in your own words; not interrupting or diverting you)
1 2 3 4 5
3) Really listening…
    (paying close attention to what you were saying; not looking at the notes or computer as you were talking)
1 2 3 4 5
4) Being interested in you as a whole person…
    (asking/knowing relevant details about your life, your situation; not treating you as ”just a number”)
1 2 3 4 5
5) Fully understanding your concerns…
    (communicating that he/she had accurately understood your concerns; not overlooking or dismissing anything)
1 2 3 4 5
6) Showing care and compassion…
    (seeming genuinely concerned, connecting with you on human level; not being indifferent or ”detached”)
1 2 3 4 5
7) Being positive…
    (having a positive approach and a positive attitude; being honest but not negative about your problems)
1 2 3 4 5
8) Explaining things clearly…
    (fully answering your questions, explaining clearly, giving you adequate information; not being vague)
1 2 3 4 5
9) Helping you take control…
    (exploring with you what you can do to improve your health yourself; encouraging rather than ”lecturing” you)
1 2 3 4 5
10) Making a plan of action with you…
      (discussing the options, involving you in decisions as much as you want to be involved; not ignoring your views)
1 2 3 4 5
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